Document:

<PAGE>

                                                                    Exhibit 10.4

                                                                  EXECUTION COPY

                                    AGREEMENT

                                     BETWEEN

                        MOUNT SINAI SCHOOL OF MEDICINE OF
                               NEW YORK UNIVERSITY

                                       AND

                            AMICUS THERAPEUTICS, INC.

LICENSE AGREEMENT

This License Agreement (the "Agreement") is made and effective as of April 15,
2002 (the "Effective Date"), by and between:

MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY, a corporation organized
and existing under the laws of the State of New York and having a place of
business at One Gustave L. Levy Place, New York, NY 10029 ("MSSM")

AND

Amicus Therapeutics, Inc., a corporation duly organized and existing under the
laws of Delaware, and having its principal office at 1055 Washington Blvd.,
Stamford, Connecticut 06901, c/o CHL Medical Partners, L.P. ("AMICUS").

RECITALS

WHEREAS:

MSSM has an ownership interest in certain Patent Rights (as hereinafter
defined); and

AMICUS wishes to obtain a license to manufacture, use, sell and offer for sale
the products covered by the Patent Rights and MSSM desires to grant such
license, all on the terms and conditions set forth herein.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
<PAGE>

NOW, THEREFORE, IT IS HEREBY DECLARED AND AGREED BETWEEN THE PARTIES AS FOLLOWS:

1.   Definitions.

Whenever used in this Agreement, the following terms shall have the following
meanings:

     a.   "Affiliate" shall mean any corporation, firm, limited liability
          company, partnership or other entity that directly or indirectly
          controls or is controlled by or is under common control with a party
          to this Agreement. "Control" means ownership, directly or through one
          or more Affiliates, of 50 percent or more of the shares of stock
          entitled to vote for the election of directors, in the case of a
          corporation, or 50 percent or more of the equity interests in the case
          of any other type of legal entity, status as a general partner in any
          partnership, or any other arrangement whereby a party controls or has
          the right to control the board of directors or equivalent governing
          body of a corporation or other entity.

     b.   "Calendar Year" shall mean any consecutive period of twelve months
          commencing on the first day of January of any year.

     c.   "Chaperones" shall mean [***].

     d.   "Conformational Diseases" shall mean [***].

     e.   "Field" shall mean [***].

     f.   "License" shall mean the license under the Patent Rights to develop,
          manufacture, have manufactured, use, offer for sale and sell the
          Licensed Products as provided in Article 2, below.

     g.   "Licensed Product" shall mean any product or part thereof, the
          manufacture, use, or sale of which is: (i) covered by one or more
          Valid Claims of any Patent Rights, or (ii) which could not be
          developed, manufactured, used, sold, comprised or delivered without
          the Patent Rights.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                        2

<PAGE>

     h.   "Net Sales" shall mean the total amount invoiced by AMICUS or by any
          AMICUS Affiliate or sub-licensee of AMICUS in connection with sales to
          any purchaser of the Licensed Products that is not an Affiliate or a
          sub-licensee of AMICUS or an AMICUS Affiliate, after deduction of all
          the following to the extent applicable to such sales;

          i)   trade, cash and quantity credits, discounts, refunds or rebates;

          ii)  allowances or credits for returns;

          iii) sales commissions;

          iv)  sales taxes (including value added tax), and

          v)   freight and insurance charges borne by the seller.

      i.  "Patent Rights" shall mean any issued patent or any patent to be
          issued pursuant to any United States or foreign patent application
          owned, by MSSM, listed in this subclause 1.i.(i)-(v) together with any
          continuations in whole or in part, divisional or substitute patents,
          any reissues or re-examinations of any such application or patents,
          and any extension of the term of any such patent in the Field. The
          issued patents and patent applications referred to in the preceding
          sentence are:

               i)   U.S. Pat. No. 6,274,597- "Method of Enhancing Lysosomal
                    AlphaGalA";

               ii)  U.S. Pat. Applic. No. 09/604,053 (continuation in part) -
                    "Method of Enhancing Mutant enzyme activities in lysosomal
                    storage disease";

               iii) U.S. Pat. Applic. No. 09/926,285 (continuation of the '597
                    Patent; and

               iv)  U.S. Pat. Applic. No. 09/948,348 (continuation of the '053
                    CIP Application.

               v)   U.S. Pat. Applic. entitled "Screen for active site specific
                    chaperones for enhancing protein folding of mutant proteins"
                    filed on March 1, 2002.

     j.   "Valid Claim" shall mean a claim of (i) an issued patent included in
          the Patent Rights which has not been declared invalid in a final,
          unappealable decision of a court of appropriate jurisdiction, or (ii)
          a pending patent application included in the Patent Rights which is
          being diligently prosecuted by or on behalf of MSSM and has not been
          formally terminated or abandoned without issuance of a patent.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                        3

<PAGE>

2.   The License

     a.   Subject to the terms and conditions hereinafter set forth, MSSM hereby
          grants to AMICUS and AMICUS hereby accepts from MSSM the world-wide
          right under the Patent Rights to develop Licensed Products for use in
          the Field and to manufacture, use, sell and offer for sale the
          Licensed Products for use in the Field. Except as set forth in Section
          2e and 8f the License shall be exclusive as to all rights of MSSM in
          and to the Patent Rights. During the term of this Agreement, MSSM
          shall make no further grant of rights in and to the Patent Rights
          inconsistent with the rights of AMICUS herein.

     b.   AMICUS shall be entitled to grant sub-licenses under the License on
          terms and conditions not inconsistent with this Agreement (except that
          the rate of royalty may be at higher rates than those set forth in
          this Agreement): (i) to an Affiliate, and (ii) to other third parties
          for consideration and in arms-length transactions.

     c.   All sub-licenses shall only be granted by AMICUS pursuant to a written
          agreement, a true and complete copy of which shall be submitted by
          AMICUS to MSSM as soon as practicable after the signing thereof. Each
          sub-license granted by AMICUS hereunder shall be subject and
          subordinate to the terms and conditions of this License Agreement and
          shall contain, inter alia, the following provisions:

          i)   the sub-license shall expire automatically on the termination of
               the License;

          ii)  the sub-license shall not be assignable, in whole or in part;

          iii) the sub-licensee shall not be entitled to grant further
               sub-licenses; and

          iv)  both during the term of the sub-license and thereafter the
               sub-licensee shall be bound by a secrecy obligation similar to
               that imposed on AMICUS in Section 6 below, and that the
               sub-licensee shall bind its employees and agents, both during the
               terms of their employment and thereafter, with a similar
               undertaking of secrecy.

     d.   The sub-license agreement shall also include the text of Sections 6, 9
          and 10 of this Agreement and shall state that MSSM is an intended
          third party beneficiary of such sub-license agreement for purposes of
          enforcing such indemnification and insurance provisions.

     e.   The License shall be subject to (i) a non-exclusive license in favor
          of the U.S. Government to the extent required by Title 35 U.S.C.A.
          Section 200 et seq., or as otherwise required by virtue of use of
          federal funding in support of inventions claimed within the Patent
          Rights and (ii) a right and license retained by MSSM on behalf of
          itself and its faculty, students and academic collaborators to
          practice the Patent Rights for its own bona fide research, including
          sponsored research and collaborations. The retained rights granted in
          this Section 2e shall not give

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                        4

<PAGE>

          MSSM the right to offer or grant rights in the Field under the Patent
          Rights to third parties.

     f.   Except for the License expressly provided in this Section 2, neither
          party hereto will, as a result of this Agreement, obtain any ownership
          interest in, or any other right or license to, any existing
          technology, patents, or Confidential Information, as defined in
          Section 6, below, of the other party.

3.   Royalty

     a.   In consideration for the grant of the License hereunder, subject to
          the provisions of Section 3.b, (i) AMICUS shall pay to MSSM [***] on
          Net Sales; and (ii) in the event AMICUS grants sublicenses with
          respect to any Licensed Product pursuant to which AMICUS receives
          remuneration other than royalties, then AMICUS shall pay to MSSM [***]
          of all payments that AMICUS receives from such sublicensee or other
          parties, including, without limitation: (a) Contract Signature
          Payments, (b) Third Party Milestone Payments, or (c) Maintenance Fees.

          As used in this Section 3.a.(ii), the term "Contract Signature
          Payment" means license initiation fees and all other up-front
          payments made to AMICUS in connection with a sublicense or similar
          agreement; "Third Party Milestone Payments" means payments made to
          AMICUS upon fulfillment by AMICUS or the sub-licensee of designated
          development objectives or regulatory requirements; and "Maintenance
          Fees" means payments (such as annual minimum royalties) made by
          sub-licensees to AMICUS to preserve, or to avoid a forfeiture of
          rights under, the sublicense agreement;

          With respect to any sublicensing or other transaction to which this
          Section 3.a.(ii) applies but which relates to products and services in
          addition to Licensed Products and for which an allocation would be
          necessary, the parties shall meet and attempt to agree on which
          portion of the total payments received by AMICUS pursuant to such
          transaction would be subject to this Section 3.a.(ii). If the parties
          cannot agree upon such allocation within a reasonable period of time,
          AMICUS shall select a nationally recognized independent certified
          public accountant, which meets MSSM's approval, to determine such
          allocation. Such allocation shall be determined in accordance with
          generally accepted accounting principles in the United States.

     b.   If AMICUS is required to acquire one or more licenses from third
          parties to make, use or sell a Licensed Product such that aggregate
          royalties payable by AMICUS on Net Sales (including the royalty amount
          due to MSSM pursuant to Section 3.a) exceeds [***], then AMICUS shall
          be entitled to a credit against the royalty payments due to MSSM
          pursuant to Section 3.a equal to [***] of the amount of such excess;
          provided, however, that in no event shall the amount otherwise payable
          to MSSM be reduced to less than [***] of Net Sales.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                        5

<PAGE>

     c.   AMICUS shall notify MSSM of the date of the first commercial sale of a
          Licensed Product as soon as practicable after the making of such
          commercial sale.

     d.   Commencing on the date of first commercial sale of a License Product,
          AMICUS shall, within 90 days from the last day of each June and
          December in each Calendar Year during the term of the License, submit
          to MSSM a full and detailed report of royalties or payments due MSSM
          under the terms of this Agreement for the preceding half year (the
          "Semi-Annual Report"), setting forth the Net Sales and lump sum
          payments and all other payments or consideration from sublicensees
          upon which such royalties are computed and including, on a Licensed
          Product-by-Licensed Product basis at least:

          i)   the quantity of Licensed Products used, sold, transferred or
               otherwise disposed of,

          ii)  the selling price of each Licensed Product,

          iii) the deductions permitted to arrive at Net Sales,

          iv)  the royalty computations and deductions therefrom based on
               royalty payments to third parties.

          If no royalties are due, a statement shall be sent to MSSM stating
          such fact. The full amount of any royalties or other payments due to
          MSSM for the preceding half-year shall accompany each such report on
          royalties and payments. AMICUS and all its sub-licensees shall keep
          for a period of at least five years after the date of entry, full,
          accurate and complete books and records consistent with sound business
          and accounting practices and in such form and in such detail as to
          enable the determination of the amounts due to MSSM from AMICUS
          pursuant to terms of this Agreement.

     e.   At the request and expense of MSSM, AMICUS shall permit (and shall
          require its sub-licensees to permit) an independent certified or
          chartered public accountant appointed by MSSM, at reasonable times
          during normal business hours and upon reasonable notice, but in any
          event no more than once per calendar year, to examine the records of
          AMICUS (and its sub-licensees) to the extent necessary to verify
          royalty calculations made hereunder; provided, however, that such
          examination shall be at the expense of AMICUS if it reveals a
          discrepancy in the amount of royalties to be paid in MSSM's favor of
          more than five percent. Results of such examination shall be made
          available to both AMICUS and MSSM.

4.   Method of Payment

     a.   Royalties and any other payments due to MSSM hereunder shall be paid
          to MSSM in United States dollars.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                        6

<PAGE>

     b.   AMICUS shall be responsible for prompt payment to MSSM of all
          royalties due on sale, transfer or disposition of Licensed Products by
          the sub-licensees of AMICUS.

     c.   As to sales occurring in currencies other than U.S. Dollars, Net Sales
          shall first be calculated in the currency in which sale occurred and
          then converted to U.S. Dollars at the buying rate for such currency
          calculated as the average of the closing buying rate for the first and
          last business day of the six month period for which royalties are due,
          as set forth in the Wall Street Journal for such dates.

5.   Development and Commercialization

     a.   AMICUS shall use its commercially reasonable efforts to bring one or
          more Licensed Products to market through a thorough, vigorous and
          diligent program for exploitation of the Patent Rights in the Field.
          AMICUS shall not, however, be required to pursue the development of
          more than one Licensed Product at a time, nor shall AMICUS be required
          to pursue every possible Licensed Product.

     b.   Attached as Appendix A to this Agreement is the current development
          plan of AMICUS for the forthcoming period of twelve months (such plan,
          as updated from time to time as described in clause (c) below, the
          "Plan"). As and when appropriate, future Plans will incorporate
          efficacy, pharmaceutical safety, toxicological and/ or clinical tests
          or any other activities necessary in order to obtain the approval of
          the FDA and counterpart foreign regulatory agencies for the
          production, use and sale of Licensed Products, as well as marketing
          plans to commercialize Licensed Products that have obtained such
          approvals.

     c.   On the earlier of thirty (30) days prior to the first anniversary of
          the Effective Date or the end of AMICUS's first fiscal year, and
          thereafter on each successive anniversary of such date, AMICUS shall
          deliver to MSSM a report setting forth in reasonable detail progress
          and problems with the implementation of the Plan and, providing an
          update on its efforts to commercialize Licensed Products, including a
          forecast and schedule of major events required to market the Licensed
          Products. Such report shall also include any amendments proposed by
          AMICUS to the Plan based upon the progress made and then current
          scientific, regulatory and commercial exigencies relating to Licensed
          Products. Within forty-five (45) days following the delivery of such a
          report (a "Diligence Report") representatives of MSSM may request a
          meeting with AMICUS to review the Diligence Report, the status of the
          efforts of AMICUS under the Plan and any proposed amendments to the
          Plan. Any such proposed amendments to the Plan shall be subject to
          approval by MSSM, which approval shall not be unreasonably withheld or
          delayed. Upon approval of any such amendments, they shall be deemed
          amendments to the Plan, added to Appendix A and deemed incorporated
          into this Agreement.

     d.   AMICUS will use its commercially reasonable efforts to accomplish the
          milestones described in the Plan.

     e.   Provided that applicable laws, rules and regulations so require, the
          manufacture of Licensed Products shall be carried out by AMICUS or its
          agents in accordance

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       7

<PAGE>

          with FDA Good Laboratory Practices and FDA Good Manufacturing Practice
          ("GMP") procedures in a facility which has been certified by the FDA
          and the performance of the tests, trials, studies and other activities
          specified in the Plan shall be so performed by AMICUS or its agents in
          accordance with FDA clinical trial procedures. MSSM shall have no
          responsibility for the actual production, distribution, sale or use of
          any Licensed Product.

     f.   If at any time AMICUS abandons or suspends its efforts to
          commercialize all Licensed Products for a period exceeding ninety (90)
          days, AMICUS shall immediately notify MSSM giving reasons and a
          statement of its intended actions. MSSM shall be entitled to terminate
          this Agreement for "Cause" in accordance with Section 11 upon any such
          abandonement.

     g.   MSSM shall also be entitled to terminate this Agreement for "Cause" in
          accordance with Section 11 if AMICUS shall fail to deliver any
          Diligence Report on a timely basis, or fail to use commercially
          reasonable efforts to implement the Plan, and such failure is not
          cured within the sixty (60) day period set by the notice provided
          pursuant to Section 11, unless such failure is excused by:

          i)   causes beyond AMICUS's direct control; or

          ii)  MSSM's failure to meet its obligations hereunder; or

          iii) inaction of any federal or state agency whose approval is
               required for commercial sales of Licensed Products.

     h.   Provided that applicable laws, rules and regulations so require, the
          performance of the tests, trials, studies and other activities
          specified in subsection b, above, shall be carried out in accordance
          with FDA Good Laboratory Practices and FDA Good Manufacturing Practice
          ("GMP") procedures in a facility which has been certified by the FDA
          as complying with GMP. MSSM shall have no responsibility for the
          actual production, distribution, sale or use of any Licensed Product.

6.   Confidential Information.

     a.   In the course of research to be performed under this Agreement, it
          will be necessary for each party to disclose "Confidential
          Information" to the other. For purposes of this Agreement,
          "Confidential Information" is defined as all information, data and
          know-how disclosed by one party (the "Disclosing Party") to the other
          (the "Receiving Party"), either embodied in tangible materials
          (including writings, drawings, graphs, charts, photographs,
          recordings, structures, technical and other information) marked
          "Confidential" or, if initially disclosed orally, which is reduced to
          writing marked "Confidential" within 21 days after initial oral
          disclosure, other than that information which is:

          i)   known by the Receiving Party at the time of its receipt, and not
               through a prior disclosure by the Disclosing Party, as documented
               by the Receiving Party's business records; or

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       8

<PAGE>

          ii)  at the time of disclosure, or thereafter becomes, published or
               otherwise part of the public domain without breach of this
               Agreement by the Receiving Party; or

          iii) obtained from a third party who has the legal right to make such
               disclosure and without any confidentiality obligation to the
               Disclosing Party; or

          iv)  independently developed by the Receiving Party without the use of
               Confidential Information received from the Disclosing Party and
               such independent development can be documented by the Receiving
               Party; or

          v)   disclosed to governmental or other regulatory agencies in order
               to obtain patents, provided that such disclosure may be made only
               to the extent reasonably necessary to obtain such patents or
               authorizations, and further provided that any such patent
               applications shall be filed in accordance with the terms of this
               Agreement; or

          vi)  required by law, regulation, rule, act or order of any
               governmental authority to be disclosed.

     b.   The Receiving Party agrees that at all times and notwithstanding any
          termination, expiration, or cancellation hereunder, it will hold the
          Confidential Information of the Disclosing Party in strict confidence,
          will use all reasonable safeguards to prevent unauthorized disclosure
          by its employees and agents. Notwithstanding the foregoing, the
          parties recognize that industry standards with respect to the
          treatment of Confidential Information may not be appropriate in an
          academic setting. However, MSSM agrees to retain Confidential
          Information of AMICUS in the same manner and with the same level of
          confidentiality as MSSM retains its own Confidential Information.

     c.   The Receiving Party will maintain reasonable procedures to prevent
          accidental or other loss, including unauthorized publication of any
          Confidential Information of the Disclosing Party. The Receiving Party
          will promptly notify the Disclosing Party in the event of any loss or
          unauthorized disclosure of the Confidential Information.

     d.   Upon termination or expiration of this Agreement, and upon written
          request, the Receiving Party will promptly return to the Disclosing
          Party all documents or other tangible materials representing
          Confidential Information and all copies thereof.

     e.   The Receiving Party will immediately notify the Disclosing Party in
          writing, if it is requested by a court order, a governmental agency,
          or any other entity to disclose Confidential Information in the
          Receiving Party's possession. The Disclosing Party will have an
          opportunity to intervene by seeking a protective order or other
          similar order, in order to limit or prevent disclosure of the
          Confidential Information. The Receiving Party will disclose only the
          minimum

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       9

<PAGE>

          Confidential Information required to be disclosed in order to comply,
          whether or not a protective order or other similar order is obtained
          by the Disclosing Party.

7.   Patent Rights.

     a.   If either party to this Agreement acquires information that a third
          party is infringing one or more of the Patent Rights, the party
          acquiring such information shall promptly notify the other party to
          Agreement in writing of such infringement.

     b.   In the event of infringement of the Patent Rights, AMICUS shall have
          the right, but not the obligation, to bring suit against the
          infringer. Should AMICUS elect to bring suit against an infringer,
          AMICUS shall be entitled to retain counsel of its own choosing, and
          shall have the right to join MSSM as party plaintiff in any such suit.
          Except as otherwise provided herein, the expenses of such suit or
          suits that AMICUS elects to bring, shall be paid for entirely by
          AMICUS and AMICUS shall hold MSSM free, clear and harmless from and
          against any and all costs of such litigation, including attorneys'
          fees. AMICUS shall not compromise or settle such litigation without
          the prior written consent of MSSM which shall not be unreasonably
          withheld.

     c.   If AMICUS shall undertake the enforcement or defense of the Patent
          Rights by litigation, AMICUS may withhold royalties otherwise
          thereafter due MSSM hereunder and apply the same toward reimbursement
          of up to [***] of AMICUS's expenses, including reasonable attorney's
          fees, in connection therewith, provided however that the maximum
          amount that can be withheld each year shall not exceed [***] of
          royalties due to MSSM in that year.

     d.   If AMICUS exercises its right to sue, it shall first reimburse itself
          out of any sums recovered in such suit or in settlement thereof for
          all costs and expenses of every kind and character, including
          reasonable attorneys' fees, necessarily involved in the prosecution of
          any such suit, and if after such reimbursement, any funds shall remain
          from said recovery, the amount of said funds shall be added to the
          amount of Net Sales for the calendar quarter in which such recovery
          was made.

     e.   If AMICUS does not bring suit against said infringer pursuant to
          subsection b, above, or has not commenced negotiations with said
          infringer for discontinuance of said infringement, within 90 days
          after receipt of such notice, MSSM shall have the right, but not the
          obligation, to bring suit for such infringement and to join AMICUS as
          a party plaintiff, in which event MSSM shall hold AMICUS free, clear
          and harmless from and against any and all costs and expenses of such
          litigation, including attorneys' fees. In the event MSSM brings suit
          for infringement of the Patent Rights, MSSM shall have the right to
          first reimburse itself out of any sums recovered in such suit or
          settlement thereof for all costs and expenses of every kind and
          character, including reasonable attorneys' fees necessarily involved
          in the prosecution of such suit, and if after such reimbursement, any
          funds shall remain from said recovery, MSSM shall promptly pay to
          AMICUS an amount equal to [***] percent of such remainder and MSSM
          shall be entitled to receive and retain the balance of the remainder
          of such recovery.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       10

<PAGE>

     f.   Each party shall have the right to be represented by counsel of its
          own selection, at its sole expense, in any suit for infringement of
          the Patent Rights instituted by the other party to this Agreement
          under the terms hereof.

     g.   AMICUS shall cooperate fully with MSSM at the request of MSSM,
          including, by giving testimony and producing documents lawfully
          requested in the course of a suit prosecuted by MSSM for infringement
          of the Patent Rights; provided MSSM shall pay all reasonable expenses
          (including attorneys' fees) incurred by AMICUS in connection with such
          cooperation. MSSM shall cooperate with AMICUS in the prosecution of a
          suit by AMICUS for infringement of the Patent Rights, provided that,
          except as otherwise provided in Section 7.f., AMICUS shall pay all
          reasonable expenses (including attorneys' fees) involved in such
          cooperation.

     h.   AMICUS shall, upon receipt of reasonable documentation, promptly
          reimburse MSSM for all of the reasonable and customary fees and
          expenses incurred by MSSM as of the Effective Date, which the parties
          expect to be approximately [***], in the prosecution and maintenance
          of the Patent Rights. In addition, AMICUS will reimburse MSSM, within
          30 days of the execution of this agreement, for [***] in total
          payments to [***] and [***] pursuant to the letter of agreement dated
          March 24, 2000 between MSSM and [***] and [***].

8.   Patent Prosecution

     a.   MSSM is the owner of the Patent Rights. MSSM has retained Darby and
          Darby, PC to prepare, file, prosecute, and maintain the pending patent
          applications and issued patents comprising the Patent Rights.

     b.   MSSM shall maintain an attorney-client relationship with Darby and
          Darby (or other patent counsel mutually agreed to by both parties
          ("Law Firm")) with respect to the Patent Rights. Nothing in this
          agreement shall prevent Amicus from establishing an attorney client
          relationship with Law Firm, except that nothing herein shall authorize
          or permit Law Firm to take any action for, or on behalf of Amicus that
          would be adverse to MSSM and/or involve a conflict of interest or a
          violation of the Code of Professional Responsibility.

     c.   From and after the Effective Date, Law Firm will interact directly
          with Amicus on all patent prosecution and patent maintenance matters
          related to the Patent Rights. Amicus shall request that the Law Firm
          send to MSSM:

               i) Copies of any document pertaining to the ongoing prosecution
               of the Patent Rights received from the U.S. Patent and Trademark
               Office, within ten (10) business days after such receipt; and

               ii) Copies of any document to be submitted to the U.S. Patent and
               Trademark Office (or any other patent granting authority) in any
               such patents or applications, at least ten (10) business days
               prior to the date

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       11

<PAGE>

               on which such document is mailed to such patent office or
               granting authority and at least twenty (20) days prior to such
               mailing date for responses to Patent Office action for which the
               Patent and Trademark Office accords a response period of more
               than thirty (30) days. Amicus shall request that Law Firm, using
               their professional judgment, accept reasonable changes that MSSM
               communicates to such counsel if such request for changes are
               received by Amicus more than five (5) business days prior to the
               date on which such document is due at the patent granting
               authority. The time limits contained in this Section 8.c.ii shall
               not apply if the application of the time allowed herein would
               create an imminent bar to patentability.

     d.   Prior to abandoning prosecution of any of the Patent Rights (or to
          abandoning any patent) covered by this Agreement, Amicus will:

               i) Notify MSSM of its intention to abandon such patent or
               application(s) at least twenty (20) days prior to the last date
               for taking action to preserve such patent or applications(s);

               ii) Permit Law Firm to continue prosecution and/or maintenance of
               such patent or application at MSSM's sole expense.

     e.   Except as otherwise expressly provided herein, Amicus shall bear all
          costs and fees incurred during the term of this Agreement in
          connection with the filing, maintenance, prosecution, protection and
          the like of the Patent Rights. Law Firm shall invoice AMICUS directly
          for all work relating to the filing, prosecution and maintenance of
          the Patent Rights and shall provide copies of all invoices to MSSM.
          AMICUS will pay invoices directly to Law Firm and copy MSSM on each
          payment.

     f.   If at any time during the term of this Agreement AMICUS decides that
          it is undesirable, as to one or more countries, to prosecute or
          maintain any patents or patent applications within the Patent Rights,
          it shall give prompt written notice thereof to MSSM, and upon receipt
          of such notice AMICUS shall be released from its obligations to bear
          all of the expenses to be incurred thereafter as to such countries in
          conjunction with such patent(s) or patent application(s). MSSM shall
          be free to grant rights in and to the released patent or patent
          applications in such countries to third parties, without further
          notice or obligation to AMICUS, and AMICUS shall have no rights
          whatsoever to exploit the released patents or patent applications in
          such countries.

     g.   Notwithstanding the foregoing, MSSM reserves the absolute right to
          countermand any instruction given by Amicus to Law Firm with respect
          to the Patent Rights.

     h.   Nothing herein contained shall be deemed to be a warranty by MSSM that
          the manufacture, use, or sale of any element of the Patent Rights or
          any Licensed Product will not infringe any patent(s) of a third party.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       12

<PAGE>

9.   Liability and Indemnification.

     a.   AMICUS shall indemnify, defend and hold harmless MSSM and its
          trustees, officers, directors, medical and professional staff,
          employees, students and agents and their respective successors, heirs
          and assigns (the "Indemnitees"), against any liability, damage, loss
          or expense (including reasonable attorneys' fees and expenses of
          litigation) incurred by or imposed upon the Indemnitees or any one of
          them in connection with any claims, suits, actions, demands or
          judgments: (i) arising out of the production, manufacture, sale, use
          in commerce or in human clinical trials, lease, or promotion by AMICUS
          or by a licensee, Affiliate or agent of AMICUS of any Licensed
          Product, process or service relating to, or developed pursuant to,
          this Agreement, or (ii) arising out of any other activities to be
          carried out pursuant to this Agreement.

     b.   AMICUS's indemnification under subsection a(i), above, shall apply to
          any liability, damage, loss or expense whether or not it is
          attributable to the negligent activities of the Indemnitees. AMICUS's
          indemnification under subsection a (ii), above, shall not apply to any
          liability, damage, loss or expense to the extent that it is
          attributable to the negligence, gross negligence or intentional
          misconduct of the Indemnitees.

     c.   AMICUS shall, at its own expense, provide attorneys reasonably
          acceptable to MSSM to defend against any actions brought or filed
          against any party indemnified hereunder with respect to the subject of
          indemnity contained herein, whether or not such actions are rightfully
          brought.

     d.   EXCEPT AS PROVIDED IN THIS SECTION 9, NEITHER PARTY SHALL BE LIABLE TO
          THE OTHER FOR INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY OR
          PUNITIVE DAMAGES.

10.  Security for Indemnification.

     a.   At such time as any Licensed Product is being commercially distributed
          or sold (other than for the purpose of obtaining regulatory approvals)
          by AMICUS or by a sub-licensee, Affiliate or agent of AMICUS and to
          the extent that it is available on commercially reasonable terms,
          AMICUS shall at its sole cost and expense, procure and maintain
          policies of comprehensive general liability insurance in amounts not
          less than [***] per incident and [***] annual aggregate and naming the
          indemnitees as additional insureds. Such comprehensive general
          liability insurance shall provide (i) product liability coverage and
          (ii) broad form contractual liability coverage for AMICUS's
          indemnification under Section 9 of this Agreement. The minimum amounts
          of insurance coverage required under this Section 10 shall not be
          construed as a limit of AMICUS's liability with respect to its
          indemnification under Section 9 of this Agreement.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       13

<PAGE>

     b.   AMICUS shall provide MSSM with written evidence of such insurance upon
          request of MSSM. AMICUS shall provide MSSM with written notice at
          least 60 days prior to the cancellation, non-renewal or material
          change in such insurance; if AMICUS does not obtain replacement
          insurance providing comparable coverage within such 60 day period
          effective immediately upon notice to AMICUS, MSSM shall have the right
          to terminate this Agreement effective at the end of such 60 day period
          without notice or any additional waiting periods.

     c.   AMICUS shall maintain such comprehensive general liability insurance
          beyond the expiration or termination of this Agreement during: (i) the
          period that any product, process or service, relating to, or developed
          pursuant to, this Agreement is being commercially distributed or sold
          (other than for the purpose of obtaining regulatory approvals) by
          AMICUS or by a licensee, Affiliate or agent of AMICUS and (ii) a
          reasonable period after the period referred to in (c)(i) above which
          in no event shall be less than seven years.

11.  Term and Termination.

     a.   This Agreement shall come into force as of the Effective Date. Unless
          sooner terminated as provided herein, this Agreement shall expire on
          the expiration of the last to expire of the Patent Rights.

     b.   At any time prior to expiration of the term of this Agreement either
          party may terminate this Agreement forthwith for cause upon notice to
          the other party. "Cause" for termination of this Agreement shall be
          deemed to exist if either MSSM or AMICUS materially breaches or
          defaults in the performance or observance of any of the provisions of
          this Agreement and such breach or default is not cured within 60 days
          or, in the case of failure to pay any amounts due hereunder, 30 days
          (unless otherwise specified herein) after the giving of notice by the
          other party specifying such breach or default, or if either MSSM or
          AMICUS discontinues its business or becomes insolvent or bankrupt.

     c.   Any amount payable hereunder by one of the parties to the other, which
          has not been paid by its due date of payment shall bear interest from
          its due date of payment until the date of actual payment, at the rate
          of two percent per annum in excess of the Prime Rate prevailing at the
          Citibank, Inc., New York, New York, during the period of arrears and
          such amount and the interest thereon may be set off against any amount
          due, whether in terms of this Agreement or otherwise, to the party in
          default by any non-defaulting party.

     d.   Upon termination of this Agreement for any reason, all rights in and
          to the Patent Rights shall revert to MSSM.

     e.   Termination of this Agreement shall not relieve the parties of any
          obligation occurring prior to such termination.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       14

<PAGE>

     f.   Sections 2e., 3e., 6, 9, 10 and 14 hereof shall survive and remain in
          full force and effect after any termination, cancellation or
          expiration of this Agreement.

12.  Representation and Covenants

     a.   MSSM hereby represents, warrants, and covenants to AMICUS that it is a
          corporation duly organized and validly existing under the laws of the
          state or other jurisdiction of its incorporation or formation;

     a.   AMICUS hereby represents, warrants and covenants to the other party
          hereto that it is a corporation duly organized and validly existing
          under the laws of the state or other jurisdiction of its incorporation
          or formation;

     b.   Each of MSSM and AMICUS hereby represents, warrants and covenants to
          the other party hereto as follows:

          i) the execution, delivery and performance of this Agreement by such
          party has been duly authorized by all requisite corporate action;

          ii) it has the power and authority to execute and deliver this
          Agreement and to perform its obligations hereunder;

          iii) the execution, delivery and performance by such party of this
          Agreement and its compliance with the terms and provisions hereof is
          not prohibited and does not and will result in a breach of any of the
          terms and provisions of, or constitute a default under, (i) a loan
          agreement, guaranty, financing agreement, agreement affecting a
          product, or other agreement or instrument binding or affecting it or
          its property; (ii) the provisions of its charter documents or bylaws;
          or (iii) any order, writ, injunction or decree of any court or
          governmental authority entered against it or by which any of its
          property is bound;

          iv) the execution, delivery and performance of this Agreement by such
          party does not require the consent, approval, or authorization of, or
          notice, declaration, filing or registration with, any governmental or
          regulatory authority, and the execution, delivery or performance of
          this Agreement will not violate any law, rule or regulation applicable
          to such party;

          v) this Agreement has been duly authorized, executed and delivered and
          constitutes such party's legal, valid and binding obligation
          enforceable against it in accordance with its terms subject, as to
          enforcement, to bankruptcy, insolvency, reorganization and other laws
          of general applicability relating to or affecting creditors' rights
          and to the availability of particular remedies under general equity
          principles; and

          vi) it shall comply with all applicable material laws and regulations
          relating to its activities under this Agreement.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       15

<PAGE>

          vii) Each party represents that performance of all the terms of this
               Agreement will not breach any agreement to keep in confidence
               proprietary information acquired by a party prior to the
               execution of this Agreement.

     c.   Except as otherwise expressly provided herein, MSSM hereby represents,
          warrants and covenants to AMICUS that:

          i)   MSSM has the full right, power and authority to grant all of the
               right, title and interest in the License; and

          ii)  there are no judgments or settlements against or owed by MSSM, or
               any pending or threatened claims or litigation relating to MSSM's
               interest in the Patent Rights; and

          iii) MSSM has not granted to any other party any rights that would
               conflict with the rights granted in this Agreement.

13.  Assignment.

     Neither party shall have the right to assign, delegate or transfer at any
     time to any party, in whole or in part, any or all of the rights, duties
     and interest herein granted without first obtaining the written consent of
     the other party to such assignment, such consent not to be unreasonably
     withheld; provided, however, that AMICUS may, with thirty (30) days prior
     written notice to MSSM, assign its rights and delegate its duties under the
     Agreement to the purchaser of substantially all of the assets of AMICUS,
     provided that the assignee agrees in writing to be bound by all the terms
     and conditions of this Agreement.

14.  Use of Name.

     Neither party may use the name of the other or its Affiliates in any
     publicity or advertising. A party may issue a press release or otherwise
     publicize or disclose this Agreement or the confidential terms and
     conditions hereof only with the prior written consent of the other party.

15.  Miscellaneous.

     a.   In carrying out this Agreement the parties shall comply with all
          local, state and federal laws and regulations including but not
          limited to, the provisions of Title 35 U.S.C.A. Section 200 et seq.
          and 15 CFR Section 368 et seq.

     b.   If any provision of this Agreement is determined to be invalid or
          void, the remaining provisions shall remain in effect.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       16

<PAGE>

     c.   This Agreement shall be deemed to have been made in the State of New
          York and shall be governed and interpreted in all respects under the
          laws of the State of New York. Any and all disputes hereunder shall be
          brought and resolved solely in the courts of the State of New York in
          and for the Borough of Manhattan.

     d.   All payments or notices required or permitted to be given under this
          agreement shall be given in writing and shall be effective when either
          personally delivered or deposited, postage prepaid, in the United
          States registered or certified mail, addressed as follows:

          To MSSM:   Mount Sinai School of Medicine of New York University
                     Attention: W. Patrick McGrath, Ph.D.
                     One Gustave L. Levy Place
                     New York, New York 10029-6574

          Copy to:   General Counsel (at the same address)

          To AMICUS: Amicus Therapeutics, Inc.
                     c/o Collinson Howe & Lennox, LLC
                     1055 Washington Blvd.
                     Stamford, CT 06901
                     Attention: Gregory Weinhoff, MD

          or such other address or addresses as either party may hereafter
          specify by written notice to the other. Such notices and
          communications shall be deemed to have been received by the addresses
          on the date of delivery if personally delivered or 14 days after
          having been sent by registered mail.

     e.   This Agreement and the exhibits attached hereto constitute the entire
          Agreement between the parties with respect to the subject matter
          hereof and no variations, modification or waiver of any of the terms
          or conditions hereof shall be deemed valid unless made in writing and
          signed by both parties hereto. This Agreement supersedes any and all
          prior agreements or understandings, whether oral or written, between
          AMICUS and MSSM.

     f.   No waiver by either party of any non-performance or violation by the
          other party of any of the covenants, obligations or agreements of such
          other party hereunder shall be deemed to be a waiver of any subsequent
          violation or non-performance of the same or any other covenant,
          agreement or obligation, nor shall forbearance by any party be deemed
          to be a waiver by such party of its rights or remedies with respect to
          such violation or non-performance.

     g.   The descriptive headings contained in this Agreement are included for
          convenience and reference only and shall not be held to expand, modify
          or aid in the interpretation, construction or meaning of this
          Agreement.

     h.   It is not the intent of the parties to create a partnership or joint
          venture or to assume partnership responsibility or liability. The
          obligations of the parties shall

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       17

<PAGE>

          be limited to those set out herein and such obligations shall be
          several and not joint.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
date first above written.

MOUNT SINAI SCHOOL OF MEDICINE          AMICUS THERAPEUTICS, INC.
OF NEW YORK UNIVERSITY

By:  /s/ Nathan Kase                    By:  /s/ Gregory Weinhoff
    ---------------------------------       ------------------------------------
Name:  Nathan Kase, M.D.                Name: Gregory M. Weinhoff
      -------------------------------
Title:  Interim Dean                    Title: Chief Executive Officer
       ------------------------------
Date:  4-15-02                          Date: April 15, 2002
      -------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       18

<PAGE>

                         AMENDMENT TO LICENSE AGREEMENT
                              DATED APRIL 15, 2002
                                     BETWEEN
                    MOUNT SINAI SCHOOL OF NEW YORK UNIVERSITY
                          AND AMICUS THERAPEUTICS INC.

Whereas the Mount Sinai School of Medicine of New York University (MSSM) and
Amicus Therapeutics Inc. (AMICUS) desire to make amendments to the License
Agreement between the two parties dated April 15, 2002.

NOW THEREFORE, IT IS HEREBY DECLARED AND AGREED BETWEEN THE PARTIES THAT THE
FOLLOWING AMENDMENTS TO THE LICENSE AGREEMENT BE EFFECTIVE AS OF ______________:

1. Under Section 1 (Definitions) the definition of "Patent Rights" shall be
amended to the following:

     i.   "Patent Rights" shall mean any issued patent or any patent to be
          issued pursuant to any United States or foreign patent application
          owned, by MSSM, listed in this subclause 1.i.(i)-(v) together with any
          continuations in whole or in part, divisional or substitute patents,
          any reissues or re-examinations of any such application or patents,
          and any extension of the term of any such patent in the Field. The
          issued patents and patent applications referred to in the preceding
          sentence are:

               i) U.S. Pat. No. 6,274,597-"Method of Enhancing Lysosomal
               AlphaGalA";

               ii) U.S. Pat. Applic. No. 09/604,053 (continuation in part)-
               "Method of Enhancing Mutant enzyme activities in lysosomal
               storage disease";

               iii) U.S. Pat. Applic. No. 09/926,285 (continuation of the '597
               Patent; and

               iv) U.S. Pat. Applic. No. 09/948,348 (continuation of the '053
               CIP Application.

               v) U.S. Pat. Applic. entitled "Screen for active site specific
               chaperones for enhancing protein folding of mutant proteins"
               filed on February 28, 2003.

               vi) US provisional patent application entitled "Combination
               Therapy For Treating Protein Deficiencies( )" filed on January
               31, 2003

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
<PAGE>

               vii) US provisional patent application entitled "Combination
               Therapy For Treating Protein Deficiencies" filed on February 18,
               2003

All other terms and conditions of the License Agreement remain unchanged and in
full force and effect.

MOUNT SINAI SCHOOL OF MEDICINE          AMICUS THERAPEUTICS, INC.
OF NEW YORK UNIVERSITY

By: /s/ Kenneth L. Davis                By: /s/ Norman Hardman
    ---------------------------------       ------------------------------------
Name: Kenneth L. Davis, M.D.            Name: Norman Hardman, Ph.D.
Title: Dean                             Title: President and CEO

Date: 3-13-03                           Date: 4.8.2003

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
<PAGE>
                                                                  Execution Copy

                         MOUNT SINAI SCHOOL OF MEDICINE
                 One Gustave L. Levy Place, New York, NY 10029

April 8, 2004

Amicus Therapeutics, Inc.
675 U.S. Highway One
North Brunswick, NJ 08902

Re:  Agreement between Mount Sinai School of Medicine of New York University
     ("MSSM") and Amicus Therapeutics, Inc. ("AMICUS") dated as of April 15,
     2002 (the "License Agreement)

Gentlemen:

This will confirm the agreement and understanding between MSSM and AMICUS
regarding an amendment to the License Agreement as follows:

1.   The definition of "Conformational Diseases" contained in Section 1.d. of
     the License Agreement is hereby amended in its entirety to read as follows:

     "Conformational Diseases" shall mean [***]

2.   The definition of "Field" contained in Section 1.e. of the License
     Agreement is hereby amended in its entirety to read as follows:

     "Field" shall mean

                         [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR
                         WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL
                         SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
                         SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
                         24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT
                         OF 1934, AS AMENDED
<PAGE>
Amicus Therapeutics, Inc.
April 8, 2004
Page 2

     [***]

3.   Section 2.c ii) of the License Agreement is hereby amended in its entirety
     to read as follows:

     2.c. ii)  the sub-license shall not be assignable, in whole or in part;
               provided, however, that the sublicensee may, written notice to
               MSSM, assign the sub-license in connection with a merger or
               acquisition of the sub-licensee or the sale by the sublicensee of
               substantially all of its assets;

4.   Section 13 of the License Agreement is hereby amended in its entirety to
     read as follows:

     Neither party shall have the right to assign, delegate or transfer at any
     time to any party, in whole or in part, any or all of the rights, duties
     and interest herein granted without first obtaining the written consent of
     the other party to such assignment, such consent not to be unreasonably
     withheld; provided, however, that AMICUS may, with written notice to MSSM,
     assign its rights and delegate its duties under the Agreement to a
     successor in interest of AMICUS by virtue of merger or acquisition or to
     the purchaser of substantially all of the assets of AMICUS, provided that
     the assignee agrees in writing to be bound by all the terms and conditions
     of this Agreement.

5.   MSSM hereby confirms that "Contract Signature Payments" and "Third Party
     Milestone Payments" as such terms are used in the License Agreement
     excludes (i) payment or reimbursement for patent expenses incurred by
     AMICUS, (ii) payment or reimbursement for the costs of research or
     development conducted by AMICUS that is sponsored by third parties or (iii)
     purchases by third parties of AMICUS securities.

6.   Except as expressly modified by this Amendment, all terms and conditions of
     the License Agreement shall remain in full force and effect.

                         [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR
                         WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL
                         SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
                         SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
                         24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT
                         OF 1934, AS AMENDED

<PAGE>
Amicus Therapeutics, Inc.
April 8, 2004
Page 3

Please indicate your acceptance of and agreement with the foregoing in the space
provided below.

Very truly yours,

Mount Sinai School of Medicine
of New York University

By:
     ------------------------
     Name:
     Title:

ACCEPTED AND AGREED

Amicus Therapeutics, Inc.

By:
     ------------------------
     Name:
     Title:

                         [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR
                         WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL
                         SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
                         SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
                         24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT
                         OF 1934, AS AMENDED<PAGE>

                                                                    Exhibit 10.5

                                LICENSE AGREEMENT

     This License Agreement (the "Agreement") is entered into by and between
UNIVERSITY OF MARYLAND, BALTIMORE COUNTY, having an address of 1000 Hilltop
Circle, Baltimore, Maryland 21250, a constituent institution of the University
System of Maryland, which is an agency of the State of Maryland (hereinafter
"UMBC"); and AMICUS THERAPEUTICS, INC., a Delaware corporation having an address
of 675 US Route 1, North Brunswick, New Jersey 08902 (hereinafter "AMICUS").

                                   WITNESSETH:

     WHEREAS, UMBC is interested in licensing PATENT RIGHTS (hereinafter
defined) in a manner that will benefit the public by facilitating the
distribution of useful products and the utilization of new methods, and as a
center for research and education, UMBC is without capacity to commercially
develop, manufacture, and distribute any such products or methods; and

     WHEREAS, a valuable invention entitled "Glycohydrolase Inhibitors, Their
Preparation and Use Thereof" (UMBC REF. 2221 MS) was developed during the course
of research conducted by Michael Sierks, Mikael Bols, and Troels Skrydstrup
(hereinafter collectively, the "Inventor(s)"); and

     WHEREAS, UMBC has acquired through assignment all rights, title and
interest to said valuable invention from the Inventors, with the exception of
certain rights retained by the United States Government; and

     WHEREAS, AMICUS desires to commercially develop, manufacture, use and
distribute products and processes derived from said invention throughout the
United States, but is unable to do so without a license from UMBC.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

     NOW THEREFORE, in consideration of the foregoing premises and the following
mutual covenants, and for other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the parties hereto agree as
follows:

                             ARTICLE 1 - DEFINITIONS

     All references to particular Exhibits and Articles shall mean the Exhibits
to, and Articles of, this Agreement, unless otherwise specified. For the
purposes of this Agreement and the Exhibits hereto, the following words and
phrases shall have the following meanings:

     1.1 "PATENT RIGHTS" shall mean the U.S. Patent No. 5,844,102, issued on
December 1,1998, and assigned to UMBC entitled "Glycohydrolase Inhibitors, Their
Preparation And Use Thereof and the invention disclosed and claimed therein, and
any, reissues, and extensions thereof.

     1.2 "LICENSED PRODUCT" as used herein in either singular or plural shall
mean any material, compositions, drug, or other product, the manufacture, use or
sale of which would constitute, but for the license granted to AMICUS pursuant
to this Agreement, an infringement of a VALID CLAIM of PATENT RIGHTS
(infringement shall include, but is not limited to, direct, contributory, or
inducement to infringe).

     1.3 "DERIVED PRODUCT" as used herein in either singular or plural shall
mean a LICENSED PRODUCT the sale of which would not, in and of itself,
constitute an infringement of a VALID CLAIM of PATENT RIGHTS (infringement shall
include, but is not limited to, direct, contributory, or inducement to
infringe), but the use or manufacture of which would constitute, but for the
license granted to AMICUS pursuant to this Agreement, an infringement of a VALID
CLAIM of PATENT RIGHTS

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                        2

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

(infringement shall include, but is not limited to, direct, contributory, or
inducement to infringe).

     1.4 "NET SALES" shall mean gross sales revenues and fees billed by AMICUS,
AFFILIATED COMPANIES, and SUBLICENSEES from the sale of LICENSED PRODUCTS less
trade discounts allowed, refunds, returns and recalls, and sales taxes. In the
event that AMICUS, an AFFILIATED COMPANY, or a SUBLICENSEE sells a LICENSED
PRODUCT in combination with other ingredients, components, substances, or as
part of a kit or system, the NET SALES for purposes of royalty payments shall be
based on the sales revenues and fees received from the entire combination, kit,
or system.

     1.5 "EXCLUSIVE LICENSE" shall mean a grant by UMBC to AMICUS and its
AFFILIATED COMPANIES of its entire right and interest in the PATENT RIGHTS
subject to the retained right of the University System of Maryland to make, have
made, provide and use LICENSED PRODUCTS for its research and educational
purposes.

     1.6 "LICENSED FIELD" shall mean the [***].

     1.7 "AFFILIATED COMPANY" as used herein in either singular or plural shall
mean any corporation, company, partnership, joint venture or other entity, which
controls, is controlled by, or is under common control with, AMICUS. For
purposes of this Paragraph, 'control' shall mean the direct or indirect
ownership of at least fifty-percent (50%).

     1.8 "SUBLICENSEE" as used herein in either singular or plural shall mean
any person or entity to which AMICUS or an AFFILIATED COMPANY has granted a
sublicense under this Agreement.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                        3

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

     1.9 "EFFECTIVE DATE" shall mean the date the last party hereto has executed
this Agreement.

     1.10 "VALID CLAIM" shall mean an issued claim in an in-force patent that
has not been held unenforceable, unpatentable, or invalid by a decision of a
government administrative agency or court of competent jurisdiction, which
finding is unappealable or unappealed within the time allowed for appeal, and
which has not been admitted to be invalid or unenforceable through reissue or
disclaimer.

                           ARTICLE II - LICENSE GRANT

     2.1 GRANT. Subject to AMICUS' payment of the fees set forth in Article III,
below, and AMICUS' and its AFFILIATED COMPANIES' compliance with the other
terms and conditions of this Agreement, UMBC hereby grants to AMICUS and its
AFFILIATED COMPANIES an EXCLUSIVE LICENSE to make, have made, use, and sell
LICENSED PRODUCTS under PATENT RIGHTS in the LICENSED FIELD.

     2.2 RIGHT TO SUBLICENSE. AMICUS and its AFFILIATED COMPANIES may sublicense
others under this Agreement, subject to UMBC's approval, which shall not be
unreasonably withheld, and shall provide a copy of each such sublicense
agreement to UMBC promptly after it is executed. UMBC shall treat all such
copies as confidential information of AMICUS. The applicable terms of any such
sublicense shall be consistent with the terms of this Agreement.

                    ARTICLE III - FEES, ROYALTIES, & PAYMENTS

     3.1 LICENSE FEE. AMICUS shall pay to UMBC [***] as a license fee, which is
nonrefundable and shall not be credited against future royalties or other fees.
UMBC will not submit an invoice for the license fee. The license fee shall be
payable as follows:

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                        4

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

     -    [***] within thirty (30) days of the EFFECTIVE DATE;

     -    [***] upon a determination that UMBC is entitled to a patent claim to
          IFG (claim 2 of the patent) or within twelve (12) months of the
          EFFECTIVE DATE, whichever comes first.

     3.2 ANNUAL FEES. AMICUS shall pay to UMBC annual fees in the amounts set
forth below until the termination or expiration of this Agreement:

<TABLE>
<CAPTION>
            DUE DATE              ANNUAL FEE
-------------------------------   ----------
<S>                               <C>
Second Anniversary of the
   Effective Date                   [***]
Third Anniversary of the
   Effective Date                   [***]
Fourth Anniversary of the
   Effective Date                   [***]
Fifth Anniversary of the
   Effective Date                   [***]
Sixth and each subsequent
   Anniversary of the Effective
   Date                             [***]
</TABLE>

These annual fees shall be due within thirty (30) days of each anniversary of
the EFFECTIVE DATE beginning with the second such anniversary. In any year
following an anniversary of the EFFECTIVE DATE where: (i) sales of LICENSED
PRODUCTS exist; (ii) milestone payments are made to UMBC pursuant to paragraph
3.4 below; or (iii) sublicensing revenues are to be paid pursuant to paragraph
3.5 below, the annual fee due on said anniversary shall be credited against such
running royalties, milestone payments, and licensing revenues due in the year
following said anniversary.

     3.3 ROYALTIES. AMICUS shall pay to UMBC [***] of NET SALES as a running
royalty for all LICENSED PRODUCTS sold by AMICUS, its AFFILIATED COMPANIES, and
SUBLICENSEES during the term of this Agreement; provided

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                        5

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

however, AMICUS, its AFFILIATED COMPANIES, and SUBLICENSEES shall pay a [***] of
NET SALES during the term of this agreement when a LICENSED PRODUCT is a DERIVED
PRODUCT. Should AMICUS be required to license patent rights from a third party
other than those already licensed by AMICUS from New York University's Mt. Sinai
School of Medicine (i.e. allowed U.S. patent applications 09/604,053 and
09/948,348, pending U.S. patent application 10/172,604, entitled "A Method For
Enhancing Mutant Enzyme Activity In Gaucher Disease," and any continuations,
divisionals, and reissues thereof) to sell a LICENSED PRODUCT, AMICUS shall be
entitled to credit [***] of any royalties payable under said third party license
against the royalties due to UMBC for such LICENSED PRODUCT, provided however,
in any case, the royalty rate payable to UMBC shall not be reduced below [***].
Royalty payments shall be made quarterly on either a calendar or fiscal
quarterly schedule, at AMICUS' election, provided said quarterly schedule is
reasonably consistent during the term of this Agreement. All non-US taxes
related to the sales of LICENSED PRODUCTS shall be paid by AMICUS and shall not
be deducted from any royalty or other payments due to UMBC.

In the event any LICENSED PRODUCT shall be sold by AMICUS or an AFFILIATED
COMPANY to an AFFILIATED COMPANY, or any person, corporation, firm or
association with which AMICUS or an AFFILIATED COMPANY has any agreement,
understanding or arrangement with respect to consideration (such as, among other
things, an option to purchase stock or actual stock ownership, or an arrangement
involving division of profits or special rebates or allowances), the royalties
to be paid hereunder for any such LICENSED PRODUCT shall be based upon the
greater of: 1) the net selling price at which the purchaser of LICENSED PRODUCTS
resells such products to the end user, 2) the fair market value of the LICENSED
PRODUCT which shall be determined based on the sales price of similar products
or services sold in the market, as applicable, or as may be mutually agreed by
the parties, or 3) the net selling price of LICENSED PRODUCTS paid to AMICUS or
an AFFILIATED COMPANY.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                        6

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

     3.4 MILESTONE PAYMENTS. AMICUS shall pay:

     1) [***] upon the first demonstration of safety and efficacy over a dosing
     interval of greater than 28 days in a human phase II clinical trial for a
     LICENSED PRODUCT; and

     2) [***] upon receiving marketing approval for a first LICENSED PRODUCT
     from the U.S. Food and Drug Administration.

     The milestone payments set forth in this Paragraph shall be credited
against running royalties due to UMBC; provided however, the amount credited in
any given year shall not exceed [***] of the running royalties that would
otherwise be due to UMBC for that year.

     3.5 SUBLICENSE CONSIDERATION. In addition to the running royalty due to
UMBC as set forth in Paragraph 3.3, AMICUS shall pay the following percentages
of any consideration, other than royalties, received by AMICUS or an AFFILIATED
COMPANY for the grant of a sublicense under this Agreement:

     1) [***] until AMICUS has identified a lead compound covered by PATENT
     RIGHTS and demonstrated safety and efficacy of said compound in an animal
     model;

     2) [***] after AMICUS has identified a lead compound covered by PATENT
     RIGHTS and demonstrated safety and efficacy of said compound in an animal
     model, but before commencement of a clinical trial on a lead compound
     covered by PATENT RIGHTS; and

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       7

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

     3) [***] following commencement of a clinical trial on a lead compound
     covered by PATENT RIGHTS.

     For the purpose of clarification, such consideration shall include, without
limitation, any licensing fees or other cash consideration, and any premium paid
by the SUBLICENSEE over Fair Market Value for stock, or stock options, of the
AMICUS or an AFFILIATED COMPANY. The term "Fair Market Value" shall mean the
daily weighted average of the price at which said stock is publicly trading
during the period twenty (20) business days prior to the effective date of said
sublicense, or if the stock is not publicly traded, the value of such stock as
determined by the most recent private financing through a Financial Investor in
AMICUS or an AFFILIATED COMPANY that issued the shares. The term "Financial
Investor" shall mean an entity whose sole interest in AMICUS or an AFFILIATED
COMPANY is for the purpose of investment.

     3.6 REIMBURSEMENT. In accordance with Paragraph 4.1 below, AMICUS will
reimburse UMBC, within thirty (30) days of the receipt of an invoice from UMBC,
for all patent office fees associated with the maintenance of PATENT RIGHTS
incurred by UMBC subsequent to the EFFECTIVE DATE of this Agreement.

     3.7 FORM OF PAYMENT. All payments under this Agreement shall be paid to
UMBC in United States Dollars by check(s) drawn on a United States Bank. Checks
are to be made payable to "UMBC" and shall reference:

         [***]

And shall be sent to:

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       8

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

          OFFICE OF TECHNOLOGY DEVELOPMENT
          UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
          ADMINISTRATION BUILDING
          1000 HILLTOP CIRCLE
          BALTIMORE, MD 21250
          ATTN: DIRECTOR

     3.8 FOREIGN CURRENCY. To the extent NET SALES of Licensed Products
manufactured in the United States are made by AMICUS or a SUBLICENSEE in a
foreign country, any royalties due to UMBC based thereon shall be first
determined in the currency of the country in which the royalties were earned and
then converted to their equivalent in United States Dollars using an average of
the currency exchange rates quoted in the Wall Street Journal for the last
business day of each of the three (3) consecutive calendar months constituting
the calendar quarter in which the royalties were earned. To the extent that
statutes, laws, codes, or government regulations (including currency exchange
regulations) shall prevent or limit royalty payments by AMICUS or its
SUBLICENSEES in any country, all monies due to UMBC shall promptly be deposited
by AMICUS or its SUBLICENSEE, as the case may be, in an account in a local bank
in such country, said bank to be designated by UMBC in writing; or paid to UMBC,
or deposited in its account, in any other country where such payment or deposit
is lawful under the currency restrictions, as directed in writing by UMBC.

     3.9 LATE PAYMENTS. In the event that any payment due hereunder is not made
when due, the payment shall accrue interest beginning on the tenth day following
the due date thereof, calculated at the annual rate of the sum of (a) two
percent (2%) plus (b) the prime interest rate quoted by The Wall Street Journal
on the date said payment is due, the interest being compounded on the last day
of each calendar quarter, provided however, that in no event shall said annual
interest rate exceed the maximum legal interest rate for corporations. Each such
payment when made shall be accompanied by all interest so accrued. Said interest
and the payment and acceptance thereof shall not negate or waive the right of
UMBC to seek any other remedy, legal or

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       9

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

equitable, to which it may be entitled because of the delinquency of any payment
including, but not limited to termination of this Agreement as set forth in
Paragraph 9.2.

     ARTICLE IV - PATENT PROSECUTION, MAINTENANCE, & INFRINGEMENT

     4.1 PROSECUTION & MAINTENANCE. UMBC, at AMICUS' expense, shall maintain all
patents specified under PATENT RIGHTS upon authorization of AMICUS and AMICUS
shall be licensed thereunder. Title to all such patents and patent applications
shall reside in UMBC. UMBC shall have full and complete control over all patent
matters related to the PATENT RIGHTS, provided however, that UMBC will consider
and incorporate reasonable comments received from AMICUS. AMICUS will provide
payment authorization to UMBC at least one (1) month before an action is due,
provided that AMICUS has received timely notice of such action from UMBC and has
the opportunity to provide comments. Failure to provide authorization can be
considered by UMBC as an AMICUS decision not to authorize an action.

     4.2 NOTIFICATION. Each party will notify the other promptly in writing when
any infringement of the PATENT RIGHTS by another is uncovered or suspected.

     4.3 INFRINGEMENT. AMICUS shall have the first right to enforce any patent
within PATENT RIGHTS in the FIELD against any infringement or alleged
infringement thereof, and shall at all times keep UMBC informed as to the status
thereof. AMICUS may, in its sole judgment and at its own expense, institute suit
against any such infringer or alleged infringer and control, settle, and defend
such suit in a manner consistent with the terms and provisions hereof and
recover, for its account subject to Paragraph 4.4, any damages, awards or
settlements resulting therefrom. This right to sue for infringement shall not be
used in an arbitrary or capricious manner. UMBC shall reasonably cooperate in
any such litigation, including being joined as a party plaintiff if AMICUS'
attorneys, in their sole discretion, determine that UMBC is necessary to any

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       10

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

such litigation, at AMICUS' expense using AMICUS' counsel of choice. UMBC shall
have the right to retain counsel of its own selection, at UMBC's expense, in any
litigation instituted by AMICUS pursuant to this Paragraph 4.3, provided that
AMICUS' counsel shall be lead counsel.

     If AMICUS elects not to enforce any patent within the PATENT RIGHTS, then
it shall so notify UMBC in writing within ninety (90) days of receiving notice
that an infringement exists, and UMBC may, in its sole judgment and at its own
expense, take steps to enforce any patent and control, settle, and defend such
suit in a manner consistent with the terms and provisions hereof, and recover,
for its own account, any damages, awards or settlements resulting therefrom.
UMBC shall reasonably consider any comments from AMICUS regarding any settlement
that may impair AMICUS' rights under this Agreement in any way prior to UMBC
entering into such settlement. AMICUS shall have the right to participate in
such litigation and, if it elects to do so, will retain counsel of its own
selection and at its expense, provided that UMBC's counsel shall be lead
counsel.

     4.4 RECOVERY. Any recovery by AMICUS under Paragraph 4.3 shall be deemed to
reflect loss of commercial sales, and AMICUS shall pay to UMBC a percent,
according to the rate determined for Sublicense Consideration as described in
Paragraph 3.5, of the recovery net of all reasonable costs and expenses
associated with each suit or settlement. If the cost and expenses exceed the
recovery, then [***] of the excess shall be credited against royalties payable
by AMICUS to UMBC hereunder in connection with sales in the country of such
legal proceedings, provided, however, that any such credit under this Paragraph
shall not exceed [***] percent [***] of the royalties otherwise payable to UMBC
with regard to sales in the country of such action in any one calendar year,
with any excess credit being carried forward to future calendar years.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       11

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

                     ARTICLE V - OBLIGATIONS OF THE PARTIES

     5.1 REPORTS. AMICUS shall provide to UMBC within thirty (30) days of the
end of each March, June, September and December after the EFFECTIVE DATE, a
written report to UMBC of the amount of LICENSED PRODUCTS sold, the total NET
SALES of such LICENSED PRODUCTS, and the running royalties due to UMBC as a
result of NET SALES AMICUS, AFFILIATED COMPANIES, and SUBLICENSEES. Payment of
any such royalties due shall accompany such report. The report of sales and
royalties due shall be substantially in the format of the sales and royalty
report form given in Exhibit A. Until AMICUS or a SUBLICENSEE has achieved a
first commercial sale of a LICENSED PRODUCT, a report shall be submitted at the
end of every June after the EFFECTIVE DATE and will include a full written
report describing AMICUS' or any SUBLICENSEE'S technical efforts towards meeting
its obligations under the terms of this Agreement as set forth in Paragraph 5.3.
UMBC shall treat all reports received pursuant to this Paragraph as confidential
information of AMICUS.

     5.2 RECORDS. AMICUS and its AFFILIATED COMPANIES shall make and retain, for
a period of three (3) years following the period of each report required by
Paragraph 5.1, true and accurate records, files and books of account containing
all the data reasonably required for the full computation and verification of
sales and other information required in Paragraph 5.1. Such books and records
shall be in accordance with generally accepted accounting principles
consistently applied. AMICUS and its AFFILIATED COMPANIES shall permit the
inspection and copying of such records, files and books of account by UMBC or
its certified public accountants during regular business hours upon ten (10)
business days' written notice to AMICUS or an AFFILIATED COMPANY. Such
inspection shall not be made more than once each calendar year. All costs of
such inspection and copying shall be paid by UMBC, provided that if any such
inspection shall reveal that an error has been made in the amount equal to five
percent (5%) or more of such payment, such costs shall be borne by AMICUS.
AMICUS and its AFFILIATED COMPANIES shall include in any

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       12

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

agreement with its SUBLICENSEES, which permits such party to make, use or sell
LICENSED PRODUCTS, a provision requiring such party to retain records of sales
of LICENSED PRODUCTS and other information as required in Paragraph 5.1 and to
permit UMBC to inspect such records as required by this Paragraph. Any
information disclosed or provided to UMBC during any such inspection or
resulting from any such inspection shall be treated as confidential information
of the disclosing party.

     5.3 COMMERCIALIZATION EFFORTS. AMICUS shall exercise commercially
reasonable efforts to develop and to introduce a LICENSED PRODUCT into the
commercial market as soon as practicable, consistent with sound and reasonable
business practice and judgment; thereafter, until the expiration of the
Agreement, AMICUS shall endeavor to keep LICENSED PRODUCTS reasonably available
to the public.

     5.4 PATENT ACKNOWLEDGEMENT. AMICUS agrees that all packaging containing
individual LICENSED PRODUCTS sold by AMICUS and SUBLICENSEES will be marked with
the number of the applicable patent(s) licensed hereunder in accordance with
each country's patent laws.

                          ARTICLE VI - REPRESENTATIONS

     6.1 REPRESENTATIONS BY UMBC. UMBC represents and warrants that it has, or
will obtain, all approvals from UMBC senior officials necessary for it to enter
into this Agreement. UMBC further warrants that it has good and marketable title
to its interest in the inventions claimed under PATENT RIGHTS with the exception
of certain retained rights of the United States government. EXCEPT AS EXPRESSLY
SET FORTH IN THIS PARAGRAPH 6.1, AMICUS AND ITS AFFILIATED COMPANIES AGREE THAT
THE PATENT RIGHTS ARE PROVIDED "AS IS", AND THAT UMBC MAKES NO REPRESENTATION OR
WARRANTY WITH RESPECT TO THE PERFORMANCE OF

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       13

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

LICENSED PRODUCTS INCLUDING THEIR SAFETY, EFFECTIVENESS, OR COMMERCIAL
VIABILITY. UMBC MAKES NO REPRESENTATION AS TO THE VALIDITY OF THE PATENT RIGHTS
OR THAT ANY PRACTICE UNDER THE PATENT RIGHTS SHALL BE FREE OF INFRINGEMENT OF
ANOTHER PATENT OR OTHER PROPRIETARY RIGHT NOT GRANTED TO AMICUS HEREUNDER. UMBC
DISCLAIMS ALL WARRANTIES WITH REGARD TO PRODUCTS AND SERVICES LICENSED UNDER
THIS AGREEMENT, INCLUDING, BUT NOT LIMITED TO, ALL WARRANTIES, EXPRESS OR
IMPLIED, OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE.
NOTWITHSTANDING ANY OTHER PROVISION OF THIS AGREEMENT, UMBC ADDITIONALLY
DISCLAIMS ALL OBLIGATIONS AND LIABILITIES ON THE PART OF UMBC AND INVENTORS, FOR
DAMAGES, INCLUDING, BUT NOT LIMITED TO, DIRECT, INDIRECT, SPECIAL, AND
CONSEQUENTIAL DAMAGES, ATTORNEYS' AND EXPERTS' FEES, AND COURT COSTS (EVEN IF
UMBC HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, FEES OR COSTS),
ARISING OUT OF OR IN CONNECTION WITH THE MANUFACTURE, USE, OR SALE OF THE
PRODUCT LICENSED UNDER THIS AGREEMENT. AMICUS AND ITS AFFILIATED COMPANIES
ASSUME ALL RESPONSIBILITY AND LIABILITY FOR LOSS OR DAMAGE CAUSED BY A LICENSED
PRODUCT MANUFACTURED, USED OR SOLD BY AMICUS, ITS SUBLICENSEES AND AFFILIATED
COMPANIES.

                          ARTICLE VII - INDEMNIFICATION

     7.1 INDEMNIFICATION. UMBC and the Inventors of PATENT RIGHTS will not,
under the provisions of this Agreement or otherwise, have control over the
manner in which AMICUS or its AFFILIATED COMPANIES or its SUBLICENSEES or those
operating for its account or third parties who purchase LICENSED PRODUCTS from
any of the foregoing entities, practice the PATENT RIGHTS or LICENSED PRODUCTS.
AMICUS shall defend, indemnify, and hold UMBC, The University System of
Maryland, the State of Maryland, their present and former trustees, officers,
agents, faculty, employees, and

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       14

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

Inventors and students who were involved with the creation of the inventions
covered by the PATENT RIGHTS, as applicable, harmless as against any judgments,
fees, expenses, or other costs arising from or incidental to any product
liability or other lawsuit, claim, demand or other action brought as a
consequence of the practice of said inventions by any of the foregoing entities,
whether or not UMBC or said Inventors, either jointly or severally, is named as
a party defendant in any such lawsuit. Practice of the inventions covered by the
PATENT RIGHTS, by an AFFILIATED COMPANY or an agent or a SUBLICENSEE or a third
party on behalf of or for the account of AMICUS or by a third party who
purchases LICENSED PRODUCTS from AMICUS, an AFFILIATED COMPANY, or a
SUBLICENSEE, shall be considered AMICUS' practice of said inventions for
purposes of this Paragraph. The obligation of AMICUS to defend, indemnify, and
hold harmless, as set forth in this Paragraph, shall survive the termination of
this Agreement.

     7.2 INDEMNIFICATION BY UMBC. UMBC will indemnify and hold AMICUS harmless
from any and all losses, claims, liabilities, damages, costs and expenses
(including reasonable attorney's fees) which arise out of the acts or omissions
of the University, its agents, employees or students in connection with this
Agreement or by any breach or default in the performance of the obligations of
the University hereunder. The obligations of UMBC pursuant to this Paragraph 7.2
are contingent upon the existence of an appropriation to UMBC by the State
Legislature for the purpose of satisfying this clause in particular or clauses
of this type, in general at the time that the acts or omissions giving rise to
the University's obligations occur. If UMBC has no such appropriation at the
time such acts or omissions occur, it will seek an appropriation to satisfy
claims pursuant to this subsection, but its obligations to pay AMICUS will be
subject to the receipt of such an appropriation.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       15

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

                         ARTICLE VIII - CONFIDENTIALITY

     8.1 CONFIDENTIALITY. In performing under this Agreement, the parties may
exchange information that they consider to be confidential. The recipient of
such information agrees to accept the disclosure of said information which is
(a) marked as confidential at the time it is sent to the recipient, or (b)
orally, is stated by the disclosing party to be confidential, or (c) is of such
a nature that the receiving party in the exercise of reasonable business
judgment should know is confidential, and to employ all reasonable efforts to
maintain the information secret and confidential, such efforts to be no less
than the degree of care employed by the recipient to preserve and safeguard its
own confidential information. The information shall not be disclosed or revealed
to anyone except employees and consultants of the recipient who have a need to
know the information and who have entered into a secrecy agreement with the
recipient under which such employees and consultants are required to maintain
confidential the proprietary information of the recipient and such employees and
consultants shall be advised by the recipient of the confidential nature of the
information and that the information shall be treated accordingly; provided
however, a receiving party may disclose confidential information to its
accountants, banks, financing sources, financial officers, lawyers, and related
professionals or such other persons having a legitimate need to know such
information, or as otherwise permitted by the disclosing party, provided that
such individuals are under an obligation to keep such information confidential.

     The obligations of this Paragraph shall also apply to the confidential
information of AFFILIATED COMPANIES and/or SUBLICENSEES provided by AMICUS to
UMBC. UMBC's, AMICUS', and its AFFILIATED COMPANIES' obligations under this
Paragraph shall extend until three (3) years after the termination of this
Agreement.

     8.2 EXCEPTIONS. The recipient's obligations under Paragraph 8.1 shall not
extend to any part of the information:

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       16

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

          A.   that can be demonstrated to have been in the public domain or
               publicly known and readily available to the trade or the public
               prior to the date of the disclosure; or

          B.   that can be demonstrated from written records to have been in the
               recipient's possession or readily available to the recipient from
               another source not under obligation of secrecy to the disclosing
               party prior to the disclosure; or

          C.   that becomes part of the public domain or publicly known by
               publication or otherwise, not due to any unauthorized act by the
               recipient; or

          D.   that is demonstrated from written records to have been developed
               by or for the receiving party without reference to confidential
               information disclosed by the disclosing party.

     8.3 COMPLIANCE WITH LAW. The prohibitions on the disclosure of confidential
information of a disclosing party under this Agreement shall not preclude a
receiving party, on the advice of counsel, from complying with applicable law or
other demand under lawful process, including a discovery request in a civil
litigation, so long as the receiving party first gives the disclosing party
written notice of the required disclosure and reasonably cooperates with the
disclosing party, at the disclosing party's sole expense, in seeking reasonable
protective arrangements with respect to such confidential information. In no
event shall the receiving party's cooperation with the disclosing party require
the receiving party to take any action that, on the advice of their counsel,
could result in the imposition of any sanctions or other penalties against it.

     8.4 RIGHT TO PUBLISH. Each party may publish manuscripts, abstracts or the
like describing the PATENT RIGHTS and inventions contained therein provided

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       17

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

confidential information of the other as defined in Paragraph 8.1, is not
included without first obtaining approval from the disclosing party to include
such confidential information. Otherwise, either party shall be free to publish
manuscripts and abstracts or the like related to the PATENT RIGHTS without the
other party's prior approval.

                         ARTICLE IX - TERM & TERMINATION

     9.1 TERM. The term of this Agreement shall commence on the EFFECTIVE DATE
and shall continue until the date of expiration of the patent included within
PATENT RIGHTS.

     9.2 TERMINATION BY EITHER PARTY. This Agreement may be terminated by either
party, in the event that the other party (a) becomes insolvent or seeks
protection under any bankruptcy, receivership, trust deed, creditors
arrangement, composition or comparable proceeding, or if any such proceeding is
instituted against a party and not dismissed within fourteen (14) days, or (b)
fails to perform or otherwise breaches any of its obligations hereunder, if,
following the giving of notice by the terminating party of its intent to
terminate and stating the grounds therefore, the party receiving such notice
shall not have cured the failure or breach within thirty (30) days. In no event,
however, shall such notice or intention to terminate be deemed to waive any
rights to damages or any other remedy that the party giving notice of breach may
have as a consequence of such failure or breach.

     9.3 TERMINATION BY AMICUS. Notwithstanding termination pursuant to
Paragraph 9.2, above, AMICUS may terminate this Agreement and the license
granted herein, for any reason, upon giving UMBC sixty (60) days written notice.

     9.4 OBLIGATIONS AND DUTIES UPON TERMINATION. If this Agreement is
terminated, both parties shall be released from all obligations and duties
imposed or assumed hereunder to the extent so terminated, except as expressly
provided to the

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       18

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

contrary in this Agreement. Upon termination, both parties shall cease any
further use of the confidential information disclosed to the receiving party by
the other party. This obligation extends as well to any other persons to whom a
party has disclosed confidential information of the other. Termination of this
Agreement, for whatever reason, shall not affect the obligation of either party
to make any payments for which it is liable prior to or upon such termination.
Termination shall not affect UMBC's right to recover unpaid royalties or fees or
reimbursement for patent expenses incurred pursuant to Paragraph 4.1 prior to
termination. At the end of the Sell-Off Period (defined below), AMICUS shall
submit a final royalty report to UMBC (which UMBC shall treat as confidential
information of AMICUS) and any royalty payments and unreimbursed patent expenses
due UMBC shall become immediately due and payable. Upon termination of this
Agreement, all rights in and to the PATENT RIGHTS shall revert immediately to
UMBC at no cost to UMBC; provided, however, that if this Agreement is terminated
pursuant to Paragraphs 9.2 or 9.3, AMICUS, its AFFILIATED COMPANIES and/or
SUBLICENSEES, shall have the right to continue to manufacture LICENSED PRODUCTS
to the extent AMICUS, its AFFILIATED COMPANIES and/or SUBLICENSEES, have parts,
components, or supplies on hand or on order, and to sell LICENSED PRODUCTS
already in inventory at the time of such termination ("Sell-Off Period"),
provided that the Sell-Off Period shall not exceed a period of one (1) year, and
subject to the royalty payment obligations of Paragraph 3.3, the reporting
provisions of Paragraph 5.1, and any other obligations that survive as set forth
in Paragraph 10.13. In the event of termination of this Agreement, AMICUS shall
provide all of its SUBLICENSEES with written notice of: (i) termination of this
Agreement; (ii) termination of all sublicenses under this Agreement; and (iii)
the right of any SUBLICENSEES to negotiate a license to PATENT RIGHTS directly
with UMBC. A copy of all such notices shall be provided to UMBC, and treated as
confidential information of AMICUS.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       19

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

                            ARTICLE X - MISCELLANEOUS

     10.1 USE OF NAME. AMICUS shall not use the name of UMBC or The University
System of Maryland or any of its constituent parts, or any contraction thereof
or the name of the Inventors in any advertising, promotional, sales literature
or fundraising documents without prior written notice to UMBC. AMICUS shall
allow at least seven (7) business days notice of any proposed public disclosure
for UMBC's review and approval. If UMBC does not respond by the end of said
seven day period, any proposed use of the names contemplated herein shall be
deemed approved provided, however, that UMBC's name shall not be used in any
case as an endorsement of LICENSED PRODUCTS.

     10.2 NO PARTNERSHIP. Nothing in this Agreement shall be construed to create
any agency, employment, partnership, joint venture or similar relationship
between the parties other than that of a licensor/licensee. Neither party shall
have any right or authority whatsoever to incur any liability or obligation
(express or implied) or otherwise act in any manner in the name or on the behalf
of the other, or to make any promise, warranty or representation binding on the
other.

     10.3 NOTICE OF CLAIM. Each party shall give the other or its representative
immediate notice of any suit or action filed, or prompt notice of any claim
made, against them arising out of the performance of this Agreement.

     10.4 PRODUCT LIABILITY. Prior to initial human testing or first commercial
sale of any LICENSED PRODUCT, as the case may be, in any particular country,
AMICUS shall establish and maintain, in each country in which AMICUS, an
AFFILIATED COMPANY or a SUBLICENSEE shall test or sell a LICENSED PRODUCT,
product liability or other appropriate insurance coverage appropriate to the
risks involved in marketing LICENSED PRODUCTS; provided however, such insurance
shall include coverage of at least [***] dollars [***] per incident. Upon
AMICUS'

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       20

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

request, UMBC agrees to reasonably consider agreeing to insurance coverage of
less than [***] dollars [***] subject to AMICUS ability to provide evidence that
a lesser amount of coverage is usual, customary, and sufficient to cover product
liability risk for LICENSED PRODUCTS or comparable products in the industry.
Upon UMBC's request, AMICUS will furnish UMBC with a Certificate of Insurance
for each product liability insurance policy obtained, which shall be treated as
confidential information of AMICUS. UMBC shall be listed as an additional
insured in AMICUS' said insurance policies. If such product liability insurance
is underwritten on a 'claims made' basis, AMICUS agrees that any change in
underwriters during the term of this Agreement will require the purchase of
'prior acts' coverage to ensure that coverage will be continuous throughout the
term of this Agreement.

     10.5 GOVERNING LAW. This Agreement shall be construed, and legal relations
between the parties hereto shall be determined, in accordance with the laws of
the State of Maryland applicable to contracts solely executed and wholly to be
performed within the State of Maryland without giving effect to the principles
of conflicts of laws. Any disputes between the parties to the Agreement shall be
brought in the state or federal courts of Maryland.

     10.6 NOTICE. All notices or communication required or permitted to be given
by either party hereunder shall be deemed sufficiently given if mailed by
registered mail or certified mail or sent by overnight courier, such as Federal
Express, to the other party at its respective address set forth below or to such
other address as one party shall give notice of to the other from time to time
hereunder. Mailed notices shall be deemed received on the third business day
following the date of mailing. Notices sent by overnight courier shall be deemed
received the following business day. Notices may be sent by facsimile provided
that any notice sent by facsimile is confirmed by registered mail or certified
mail or sent by overnight courier. Notices received by facsimile shall be deemed
received on the day either party receives such a facsimile at the number listed
below.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       21

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

     If to AMICUS:   Amicus Therapeutics, Inc.
                     675 US Highway One
                     North Brunswick, NJ 08902
                     Attn: Vice President of Research

                     Facsimile: 732-745-9769

     If to UMBC:     Office of Technology Development
                     University of Maryland, Baltimore County
                     Administration Building, 2nd Floor
                     1000 Hilltop Circle
                     Baltimore, MD 21250
                     Attn: Director

                     Facsimile: 410-455-8750

     10.7 COMPLIANCE WITH ALL LAWS. In all activities undertaken pursuant to
this Agreement, both UMBC and AMICUS covenant and agree that each will in all
material respects comply with applicable federal, state and local laws and
statutes, as may be in effect at the time of performance and all valid rules,
regulations and orders thereof regulating such activities.

     10.8 SUCCESSORS AND ASSIGNS. Neither this Agreement nor any of the rights
or obligations created herein, except for the right to receive any remuneration
hereunder, may be assigned by either party, in whole or in part, without the
prior written consent of the other party, except that either party shall be free
to assign this Agreement in connection with any sale of all or substantially all
of its assets, stock or business to which this Agreement relates (whether by
sale, merger, acquisition, operation of law or otherwise) without the consent of
the other. AMICUS shall promptly notify UMBC of any such assignment by AMICUS.
This Agreement shall bind and inure to the benefit of the successors and
permitted assigns of the parties hereto. Any attempt to assign this Agreement
other than as expressly permitted by this Paragraph shall render the attempted
assignment null and void.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       22

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

     10.9 NO WAIVERS; SEVERABILITY. No waiver of any breach of this Agreement
shall constitute a waiver of any other breach of the same or other provision of
this Agreement, and no waiver shall be effective unless made in writing. Any
provision hereof prohibited by or unenforceable under any applicable law of any
jurisdiction shall as to such jurisdiction be deemed ineffective and deleted
herefrom without affecting any other provision of this Agreement. It is the
desire of the parties hereto that this Agreement be enforced to the maximum
extent permitted by law, and should any provision contained herein be held by
any governmental agency or court of competent jurisdiction to be void, illegal
and unenforceable, the parties shall negotiate in good faith for a substitute
term or provision which carries out the original intent of the parties

     10.10 ENTIRE AGREEMENT; AMENDMENT. AMICUS and UMBC acknowledge that they
have read this entire Agreement and that this Agreement, including the attached
Exhibits constitutes the entire understanding and contract between the parties
hereto and supersedes any and all prior or contemporaneous oral or written
communications with respect to the subject matter hereof, all of which
communications are merged herein. It is expressly understood and agreed that (i)
there being no expectations to the contrary between the parties hereto, no usage
of trade, verbal agreement or another regular practice or method dealing within
any industry or between the parties hereto shall be used to modify, interpret,
supplement or alter in any manner the express terms of this Agreement; and (ii)
this Agreement shall not be modified, amended or in any way altered except by an
instrument in writing signed by both of the parties hereto.

     10.11 FORCE MAJEURE. If either party fails to fulfill its obligations
hereunder (other than an obligation for the payment of money), when such failure
is due to an act of God, or other circumstances beyond its reasonable control,
including but not limited to fire, flood, civil commotion, riot, war (declared
and undeclared), revolution, or embargoes, then said failure shall be excused
for the duration of such event and for such a time thereafter as is reasonable
to enable the parties to resume performance under this Agreement.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       23

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

     10.12 FURTHER ASSURANCES. Each party shall, at any time, and from to time,
prior to or after the EFFECTIVE DATE of this Agreement, at reasonable request of
the other party, execute and deliver to the other such instruments and documents
and shall take such actions as may be required to more effectively carry out the
terms of this Agreement.

     10.13 SURVIVAL. All representations, warranties, covenants and agreements
made herein and which by their express terms or by implication are to be
performed after the execution and/or termination hereof, or are prospective in
nature, shall survive such execution and/or termination, as the case may be.
This shall include Articles VI, VII, VIII, IX, and X, including, but not limited
to, AMICUS' right to make, use, and sell LICENSED PRODUCTS during the Sell-Off
Period and its obligation to pay royalties as set forth in Paragraph 9.4.

     10.14 NO THIRD PARTY BENEFICIARIES. Nothing in this Agreement shall be
construed as giving any person, firm, corporation or other entity, other than
the parties hereto and their successors and permitted assigns, any right, remedy
or claim under or in respect of this Agreement or any provision hereof.

     10.15 HEADINGS. Article headings are for convenient reference and not a
part of this Agreement. All Exhibits are incorporated herein by this reference.

     10.16 COUNTERPARTS. This Agreement may be executed in counterparts, each of
which shall be deemed an original and all of which when taken together shall be
deemed but one instrument.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       24

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

     IN WITNESS WHEREOF, the parties have caused this Agreement to be executed
by their duly authorized representatives as of the date the last party hereto
has executed this Agreement.

UNIVERSITY OF MARYLAND, BALTIMORE       AMICUS THERAPEUTICS, INC.
COUNTY

By: /s/ Scott A. Bass                   By: /s/ Norman Hardman
    ---------------------------------       ------------------------------------
    Scott A. Bass, Ph.D.                    Norman Hardman, Ph.D.
    Vice Provost for Research               Chief Executive Officer

Date: 6/19/03                           Date: 6.26.03

APPROVED
UMBC Legal Affairs

/s/ Illegible
-------------------------------------

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       25

<PAGE>

AMICUS THERAPEUTICS, INC.
Exclusive License Agreement

                                    EXHIBIT A

                        QUARTERLY SALES & ROYALTY REPORT
          FOR LICENSE AGREEMENT BETWEEN AMICUS AND UMBC DATED _________

                  FOR PERIOD OF ______________ TO ____________

<TABLE>
<CAPTION>
             UMBC              TOTAL NET
PRODUCT   REFERENCE/           SALES/NET             ROYALTY
 NAME/      PATENT     UNITS    SERVICE    ROYALTY    AMOUNT
 NUMBER     NUMBER      SOLD    REVENUES     RATE      DUE
-------   ----------   -----   ---------   -------   -------
<S>       <C>          <C>     <C>         <C>       <C>

</TABLE>

                     TOTAL ROYALTIES DUE FOR THIS PERIOD $______________________

   This report format is to be used to report quarterly royalty statements to
    UMBC. It should be placed on AMICUS letterhead and accompany any royalty
  payments due for the reporting period. This report shall be submitted even if
                             no sales are reported.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}]]